On the other hand, the negative impact of A2AR on anti-tumor immunity was shown in a combined trial of PD-L1 and A2AR inhibitors in renal cell carcinoma (RCC), demonstrating better clinical responses to A2AR inhibitors when tumors exhibited high adenosine signature profiles (81). The gene discussed is ADORA2A; the disease is renal cell carcinoma.